摘要
目的 检测非小细胞肺癌 (NSCLC)多药耐药相关基因及细胞凋亡基因的表达 ,探讨其表达的相关性及临床病理意义。方法 采用SP免疫组化法检测 113例NSCLC中多药耐药相关蛋白 (MRP)、谷胱甘肽巯基转移酶π(GST π)、肺耐药相关蛋白 (LRP)、突变型 p5 3和bcl 2的表达。 结果 NSCLC中MRP、GST π、LRP、p5 3和bcl 2的检出率分别为79.6 5 %、75 .2 2 %、80 .5 3%、6 1.95 %、5 9.2 9%。MRP、LRP和bcl 2的表达与组织学类型有关 (P <0 .0 5 )。p5 3与肿瘤细胞的分化程度有关 (P <0 .0 5 ) ,随着肿瘤细胞分化的恶性程度增加呈递增趋势。MRP与GST π、LRP表达之间 ,p5 3和bcl 2表达之间相关性有统计学意义 (P <0 .0 5 )。结论 不同组织学类型NSCLC的多药耐药性各不相同 ,且其耐药性之间还存在一定的相关性。检测NSCLC的多药耐药性有助于指导肺癌的化疗。
Objective To investigate the expression level and clinicopathological significance of the multi-drug resistance (MDR) associated genes and apoptosis genes in non-small cell lung carcinoma (NSCLC). Methods NSCLC from 113 patients were analyzed immunohistochemically with antibodies to MRP, GST-π, LRP, mutant p53 and bcl-2. Results The following percentages of cases were positive for each marker: MRP( 79.65% )?GST-π( 75.22% )?LRP( 80.53% )?mutant p53 ( 61.95% )?and bcl-2 ( 59.29% ). Significant correlation was observed among the expression of MRP, LRP, bcl-2 and histological types( P < 0.05 ). The expression of mutant p53 in NSCLC was associated with carcinoma cell differentiation ( P < 0.05 ). The higher the expression level of p53 was, the poorer carcinoma cell differentiation was. The expressions were significantly related between MRP and GST-π, MRP and LRP, mutant p53 and bcl-2 ( P < 0.05 ). Conclusion Different histological types of NSCLC had different expression of multi-drug resistance related genes, and some relationship existed among these multi-drug resistances related genes. Assays of these multi-drug resistance related genes will be useful to direct chemotherapy of lung carcinoma clinically.
出处
《肿瘤防治研究》
CAS
CSCD
2004年第1期9-11,共3页
Cancer Research on Prevention and Treatment
基金
湖北省自然科学基金资助项目 (2 0 0 2AB14 5 )
科技攻关计划项目 (2 0 0 2AA30 4B13)